Léky

Schválené léky

Přehled nově schválených registrací a indikací.

Specifický léčebný program – kvetiapin, tablety s prodlouženým uvolňováním

SUKL · 31. 7. 2026

Státní ústav pro kontrolu léčiv informuje o mimořádné potřebě léčivého přípravku kvetiapin s prodlouženým uvolňováním v silách 50 mg, 150 mg, 200 mg, 300 mg a 400 mg, které nejsou v ČR dostupné z důvodu přerušení nebo ukončení dodávek. Nedostupnost lze pokrýt specifickým léčebným programem a vyzývá se k předložení návrhu.

Schválené léky

Specifický léčebný program – kvetiapin, tablety s prodlouženým uvolňováním

Informace o výskytu padělku léčivého přípravku Mounjaro

Iclusig (ponatinib) - European Medicines Agency

Qoyvolma (ustekinumab) - EMA

Kaftrio, ivacaftor, tezacaftor, elexacaftor

Multaq (dronedarone) - European Public Assessment Report

Aspaveli (pegcetacoplan) authorised by EMA

FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

Sylvant (siltuximab) authorised by EMA

Gilenya (fingolimod) - European public assessment report

Xofigo (radium Ra223 dichloride)

Mayzent (siponimod) authorised in the EU

Jascayd (nerandomilast) authorised by EMA

Boey (trenibotulinumtoxinE) Authorised by EMA

Similasan AG - 658878 - 07/29/2026

Similasan AG - 658878 - 09/11/2023

Vydání stanoviska MDCG 2026-5 k přidělování UDI mezi výrobci a distributory

Oprava Seznamu cen a úhrad LP k 1. 8. 2026

PecFent (fentanyl) Authorised by EMA

Template - Application for transfer of marketing authorisation from transferor to transferee, attachment 1 (veterinary)

Rxulti (brexpiprazole) Authorised by EMA

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 35, Status: Withdrawn

Seznam cen a úhrad LP k 1. 8. 2026

Seznam léčiv nehrazených ze zdravotního pojištění k 1. 8. 2026

Nová možnost léčby neovaskulární (vlhké) formy věkem podmíněné makulární degenerace

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Date of authorisation: 19/01/2007, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Apixaban Accord, apixaban, Date of authorisation: 23/07/2020, Revision: 8, Status: Authorised

Electronic Registration and Listing Compliance Program

Human medicines European public assessment report (EPAR): Macitentan AccordPharma, macitentan, Date of authorisation: 24/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Macitentan Accord, macitentan, Date of authorisation: 24/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 22, Status: Authorised

Desloratadine Teva - EMA

European Medicines Agency’s data protection notice for meeting registration forms via Microsoft Forms

European Medicines Agency’s data protection notice for meeting registration forms via EUSurvey

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 61, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 62, Status: Authorised

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

Informační dopis – Paricalcitol Fresenius

Informační dopis – Vyvgart

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 8, Status: Authorised

Specifický léčebný program – klonazepam pro intravenózní/intramuskulární podání

Informace o výskytu padělků léčivého přípravku Mounjaro

Kigabeq (vigabatrin) authorised by EMA

Lumykras (sotorasib) authorised by EMA

Orkambi, lumacaftor, ivacaftor

Cometriq, cabozantinib

European Medicines Agency (EMA) Authorises Ryjunea (atropine sulfate)

Informační dopis – Tolucombi

Voranigo (vorasidenib) authorised by EMA

Ultomiris (ravulizumab) authorised by EMA

Takhzyro (lanadelumab) - EMA Authorisation

Darzalex (daratumumab) Authorised by EMA

Opdualag, relatlimab, nivolumab

Warning Letter Issued to NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

Warning Letter Issued to NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

Věstník 7/2026

Specifický léčebný program – glichidon

Retacrit (epoetin zeta) - EMA Authorisation

EMA Authorises Ogsiveo (nirogacestat)

Pluvicto (lutetium (177Lu) vipivotide tetraxetan) - EMA Authorisation

Scemblix (asciminib) authorised by EMA

Yondelis (trabectedin) - European Medicines Agency

Written Requests Issued

Specifický léčebný program – terbutalin-sulfát pro subkutánní/intravenózní podání

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 12, Status: Authorised

FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 4, Status: Authorised

Informační dopis – Tavneos (avakopan)

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Date of authorisation: 13/12/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 6, Status: Authorised

Pediatric Exclusivity Granted

FDA Issues Warning Letter to Wholesale Peptide

FDA Issues Warning Letter to MantroForce